Phase I/II adaptive dose-finding design for combination studies where toxicity rates are supposed to increase with both agents.
Latest Versions
66 versions →| Version | Vulnerabilities | Usages | Date | |
|---|---|---|---|---|
3.0.x | 3.0-0-b1 |
0
| Feb 14, 2021 | |
2.6.x | 2.6-0-b1 |
0
| Feb 14, 2021 | |
2.5.x | 2.5-0-b3 |
0
| Feb 14, 2021 | |
| 2.5-0-b2 |
0
| Feb 14, 2021 | ||
| 2.5-0-b1 |
0
| Feb 14, 2021 | ||
2.3.x | 2.3-b10 |
0
| Feb 14, 2021 | |
| 2.3-b9 |
0
| Feb 14, 2021 | ||
| 2.3-b7 |
0
| Feb 14, 2021 | ||
2.1.x | 2.1-6-b14 |
0
| Feb 14, 2021 | |
| 2.1-6-b13 |
0
| Feb 14, 2021 | ||
| 2.1-6-b12 |
0
| Feb 14, 2021 | ||
2.0.x | 2.0-2-b201 |
0
| Jan 20, 2018 | |
1.0.x | 1.0-1-b201 |
0
| Jan 20, 2018 | |
| 1.0-b201 |
0
| Jan 20, 2018 |
